Analytical similarity for biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Analytical similarity for biosimilars

INICIO/Informes | Posted 06/07/2018 0 Post your comment

Dr Patrick Lynch, Product Quality Reviewer at the US Food and Drug Administration (FDA), gave a presentation on demonstrating analytical similarity for biosimilars at the US Drug Information Association’s Biosimilars Conference [1].

In the US, a legal framework for approving biosimilars was established in 2009, via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). As part of the Food and Drug Administration’s (FDA) implementation of the BPCI Act, the agency published draft guidance on biosimilar interchangeability in January 2017 [2].

Dr Lynch made the following recommendations about demonstrating analytical similarity for biosimilars:

A well‐planned and comprehensive analytical programme allows for evaluation of analytical similarity based on a totality‐of‐the evidence approach
Failure to meet predefined acceptance criteria on a statistical test does not necessarily preclude determination of ‘highly similar’
A robust analytical similarity programme that includes in‐depth structural and functional characterization improves the likelihood that any analytical differences between highly similar products can be addressed
Plan ahead to ensure sufficient numbers of independent lots are available for statistically rigorous evaluation

His presentation covered expectations for analytical similarity studies, including analytical considerations, ranking and evaluation of quality attributes and lot selection/handling, as well as how to address uncertainty, which included discussion of structure–function relationships and example case studies.

These subjects are covered in more detail in the following series of four articles.

Disclaimer
Dr Patrick Lynch, Product Quality Reviewer at the US Food and Drug Administration (FDA), stated that his presentation reflects the views of the author and should not be construed to represent FDA’s views or policies.

Related articles
Addressing uncertainty in biosimilarity

Lot selection and handling for biosimilarity

Ranking and evaluation of quality attributes for biosimilarity

Analytical consideration in demonstrating similarity for biosimilars

References
1. Lynch P. Expectations and approaches for demonstrating analytical similarity. DIA Biosimilars Conference; 24-25 October 2017; Bethesda, Maryland, USA.
2. GaBI Online - Generics and Biosimilars Initiative. FDA issues draft guidance on biosimilar interchangeability [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jul 6]. Available from: www.gabionline.net/Guidelines/FDA-issues-draft-guidance-on-biosimilar-interchangeability

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.